|
1
|
Ferlay J, Parkin DM and Steliarova-Foucher
E: Estimates of cancer incidence and mortality in Europe in 2008.
Eur J Cancer. 46:765–781. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Azzoli CG, Baker S Jr, Temin S, et al:
American Society of Clinical Oncology Clinical Practice Guideline
update on chemotherapy for stage IV non-small-cell lung cancer. J
Clin Oncol. 27:6251–6266. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Lynch TJ, Bell DW, Sordella R, et al:
Activating mutations in the epidermal growth factor receptor
underlying responsiveness of non-small-cell lung cancer to
gefitinib. N Engl J Med. 350:2129–2139. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Maemondo M, Inoue A, Kobayashi K, et al:
Gefitinib or chemotherapy for non-small-cell lung cancer with
mutated EGFR. N Engl J Med. 362:2380–2388. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Mitsudomi T, Morita S, Yatabe Y, et al:
Gefitinib versus cisplatin plus docetaxel in patients with
non-small-cell lung cancer harbouring mutations of the epidermal
growth factor receptor (WJTOG3405): an open label, randomised phase
3 trial. Lancet Oncol. 11:121–128. 2010. View Article : Google Scholar
|
|
6
|
Mok TS, Wu YL, Thongprasert S, et al:
Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N
Engl J Med. 361:947–957. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Rosell R, Carcereny E, Gervais R, et al:
Erlotinib versus standard chemotherapy as first-line treatment for
European patients with advanced EGFR mutation-positive
non-small-cell lung cancer (EURTAC): a multicentre, open-label,
randomised phase 3 trial. Lancet Oncol. 13:239–246. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Zhou C, Wu YL, Chen G, et al: Erlotinib
versus chemotherapy as first-line treatment for patients with
advanced EGFR mutation-positive non-small-cell lung cancer
(OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase
3 study. Lancet Oncol. 12:735–742. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Han JY, Park K, Kim SW, et al:
First-SIGNAL: first-line single-agent iressa versus gemcitabine and
cisplatin trial in never-smokers with adenocarcinoma of the lung. J
Clin Oncol. 30:1122–1128. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Paez JG, Janne PA, Lee JC, et al: EGFR
mutations in lung cancer: correlation with clinical response to
gefitinib therapy. Science. 304:1497–1500. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Pao W, Miller V, Zakowski M, et al: EGF
receptor gene mutations are common in lung cancers from ‘never
smokers’ and are associated with sensitivity of tumors to gefitinib
and erlotinib. Proc Natl Acad Sci USA. 101:13306–13311. 2004.
View Article : Google Scholar
|
|
12
|
Shigematsu H, Lin L, Takahashi T, et al:
Clinical and biological features associated with epidermal growth
factor receptor gene mutations in lung cancers. J Natl Cancer Inst.
97:339–346. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Han SW, Kim TY, Hwang PG, et al:
Predictive and prognostic impact of epidermal growth factor
receptor mutation in non-small-cell lung cancer patients treated
with gefitinib. J Clin Oncol. 23:2493–2501. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Kosaka T, Yatabe Y, Endoh H, Kuwano H,
Takahashi T and Mitsudomi T: Mutations of the epidermal growth
factor receptor gene in lung cancer: biological and clinical
implications. Cancer Res. 64:8919–8923. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Pao W and Ladanyi M: Epidermal growth
factor receptor mutation testing in lung cancer: searching for the
ideal method. Clin Cancer Res. 13:4954–4955. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Mitsudomi T and Yatabe Y: Mutations of the
epidermal growth factor receptor gene and related genes as
determinants of epidermal growth factor receptor tyrosine kinase
inhibitors sensitivity in lung cancer. Cancer Sci. 98:1817–1824.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Hall JG, Eis PS, Law SM, et al: Sensitive
detection of DNA polymorphisms by the serial invasive signal
amplification reaction. Proc Natl Acad Sci USA. 97:8272–8277. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Naoki K, Soejima K, Okamoto H, et al: The
PCR-invader method (structure-specific 5′ nuclease-based method), a
sensitive method for detecting EGFR gene mutations in lung cancer
specimens; comparison with direct sequencing. Int J Clin Oncol.
16:335–344. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Nagai Y, Miyazawa H, Huqun, et al: Genetic
heterogeneity of the epidermal growth factor receptor in non-small
cell lung cancer cell lines revealed by a rapid and sensitive
detection system, the peptide nucleic acid-locked nucleic acid PCR
clamp. Cancer Res. 65:7276–7282. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Yatabe Y, Hida T, Horio Y, Kosaka T,
Takahashi T and Mitsudomi T: A rapid, sensitive assay to detect
EGFR mutation in small biopsy specimens from lung cancer. J Mol
Diagn. 8:335–341. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Kimura H, Kasahara K, Kawaishi M, et al:
Detection of epidermal growth factor receptor mutations in serum as
a predictor of the response to gefitinib in patients with
non-small-cell lung cancer. Clin Cancer Res. 12:3915–3921. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Takata M, Chikumi H, Miyake N, et al: Lack
of AKT activation in lung cancer cells with EGFR mutation is a
novel marker of cetuximab sensitivity. Cancer Biol Ther.
13:369–378. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Fujimoto T, Konagaya M, Enomoto M, et al:
Novel high-speed real-time PCR method (Hyper-PCR): results from its
application to adenovirus diagnosis. Jpn J Infect Dis. 63:31–35.
2010.PubMed/NCBI
|
|
24
|
Barbau-Piednoir E, Botteldoorn N, Yde M,
Mahillon J and Roosens NH: Development and validation of
qualitative SYBR®Green real-time PCR for detection and
discrimination of Listeria spp. and Listeria monocytogenes. Appl
Microbiol Biotechnol. 97:4021–4037. 2013. View Article : Google Scholar :
|
|
25
|
Bustin SA: Absolute quantification of mRNA
using real-time reverse transcription polymerase chain reaction
assays. J Mol Endocrinol. 25:169–193. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Newton CR, Graham A, Heptinstall LE, et
al: Analysis of any point mutation in DNA. The amplification
refractory mutation system (ARMS). Nucleic Acids Res. 17:2503–2516.
1989. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Newton CR, Kalsheker N, Graham A, et al:
Diagnosis of α1-antitrypsin deficiency by enzymatic
amplification of human genomic DNA and direct sequencing of
polymerase chain reaction products. Nucleic Acids Res.
16:8233–8243. 1988. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Ellison G, Zhu G, Moulis A, Dearden S,
Speake G and McCormack R: EGFR mutation testing in lung cancer: a
review of available methods and their use for analysis of tumour
tissue and cytology samples. J Clin Pathol. 66:79–89. 2013.
View Article : Google Scholar :
|
|
29
|
Goto K, Satouchi M, Ishii G, et al: An
evaluation study of EGFR mutation tests utilized for non-small-cell
lung cancer in the diagnostic setting. Ann Oncol. 23:2914–2919.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Kim YH, Yang I, Bae YS and Park SR:
Performance evaluation of thermal cyclers for PCR in a rapid
cycling condition. Biotechniques. 44:495–496. 498500passim. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Nitsche A: Oligonucleotide design for
in-house real-time PCR applications in microbiology. Real-Τime PCR
in Microbiology. Mackay IM: Caister Academic Press; Norfolk: pp.
41–69. 2007
|
